Merit Medical Systems stock rating reaffirmed by Piper Sandler

Piper Sandler reiterated an Overweight rating on Merit Medical Systems (MMSI) with a $105 price target, citing strong execution on growth initiatives, solid 10.11% LTM revenue growth, and the accretive potential of its WRAPSODY product. This positive sentiment is bolstered by MMSI's Q2 2025 earnings beat, reporting EPS of $1.01 and revenue of $382.5 million, with organic revenue growth improving to 6.7% YoY, which also led Needham to reiterate a Buy rating. The company further demonstrated momentum through its SCOUT Radar Localization system reaching 750,000 patients and securing EU approval for Embosphere Microspheres, signaling continued product innovation and market expansion.

Analysis

Merit Medical Systems (MMSI) is demonstrating significant operational momentum and has garnered strong positive sentiment from Wall Street, supported by tangible financial results and strategic progress. Piper Sandler's reiterated 'Overweight' rating and $105 price target are underpinned by the company's accelerated execution of its three-year growth plan, robust last-twelve-months revenue growth of 10.11%, and a healthy 47.95% gross profit margin. This optimism is validated by the company's second-quarter 2025 performance, which saw an earnings beat with an EPS of $1.01 against a forecast of $0.85 and revenue of $382.5 million versus a $374.18 million projection. Critically, organic revenue growth accelerated to 6.7% year-over-year, signaling strengthening core business fundamentals, a view reinforced by Needham's reiterated 'Buy' rating and $108 price target. Future growth catalysts are also materializing, with the WRAPSODY product highlighted as a key accretive driver for the 2026 plan, while recent milestones, including the SCOUT Radar Localization system reaching 750,000 patients and EU approval for Embosphere Microspheres, showcase successful innovation and market expansion.

Key Decisions for Investors

• The strong analyst consensus, with price targets from Piper Sandler ($105) and Needham ($108) implying significant upside from the current price of $82.46, warrants a bullish evaluation of the stock.
• Investors should closely monitor upcoming quarterly results for continued earnings beats and raises, specifically tracking for sustained organic revenue growth above the recent 6.7% and margin strength to validate the current thesis.
• The commercial rollout and revenue contribution of the WRAPSODY product, along with market penetration following the EU approval for Embosphere, are key catalysts that should be watched as primary drivers of future value.
• Given the stock is presented as potentially undervalued with strong fundamentals, including a current ratio of 4.09, investors may consider the current valuation an attractive entry point relative to its demonstrated execution and growth outlook.